Yasuhide Yamada
- Oncology top 0.2%
- Colorectal Cancer Treatments and Studies 135
- Cancer Treatment and Pharmacology 62
- HER2/EGFR in Cancer Research 24
- Gastroenterology top 0.5%
- Gastrointestinal Tumor Research and Treatment 26
- Cancer Research top 0.5%
- Pulmonary and Respiratory Medicine top 0.5%
- Gastric Cancer Management and Outcomes 121
- Lung Cancer Treatments and Mutations 33
- Hepatology top 1%
- Hepatocellular Carcinoma Treatment and Prognosis 26
-
- Cholangiocarcinoma and Gallbladder Cancer Studies 26
- Co-authors
- Yasuhiro ShimadaTetsuya HamaguchiKen KatoKuniaki ShiraoAtsushi OhtsuKei MuroNoboru YamamotoYasuhiro Matsumura
- Partner nations
- JapanUnited StatesUnited Kingdom
In The Last Decade
Yasuhide Yamada
299 papers receiving 10.7k citations
Hit Papers
Peers
Comparison fields: 5 of 136
- Oncology 5.3k
- Gastroenterology 971
- Cancer Research 1.9k
- Pulmonary and Respiratory Medicine 3.8k
- Hepatology 631
Countries citing papers authored by Yasuhide Yamada
This map shows the geographic impact of Yasuhide Yamada's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yasuhide Yamada with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yasuhide Yamada more than expected).
Fields of papers citing papers by Yasuhide Yamada
This network shows the impact of papers produced by Yasuhide Yamada. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yasuhide Yamada. The network helps show where Yasuhide Yamada may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Yasuhide Yamada, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2024 | 2 | |
| 3 | 2023 | 7 | |
| 4 | 2021 | 0 | |
| 5 | 2020 | 6 | |
| 6 | 2019 | 12 | |
| 7 | 2018 | 33 | |
| 8 | 2018 | 92 | |
| 9 | 2016 | 10 | |
| 10 | 2016 | 54 | |
| 11 | 2015 | 9 | |
| 12 | Phase I study of combination therapy with irinotecan, leucovorin, and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for advanced colorectal cancer in Japanese patients. | 2014 | 2 |
| 13 | Irinotecan plus cisplatin in patients with extensive-disease poorly differentiated neuroendocrine carcinoma of the esophagus. | 2014 | 24 |
| 14 | 2012 | 33 | |
| 15 | 2011 | 140 | |
| 16 | 2010 | 157 | |
| 17 | [Impact of HER2, EGFR, IGF-1R, and VEGFR expressions on the outcome of chemotherapy for advanced gastric cancer]. | 2010 | 4 |
| 18 | 2009 | 114 | |
| 19 | 2008 | 50 | |
| 20 | 2007 | 52 |
About Yasuhide Yamada
Yasuhide Yamada is a scholar working on Oncology, Gastroenterology and Pulmonary and Respiratory Medicine, having authored 308 papers that have together received 10.9k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (135 papers), Gastric Cancer Management and Outcomes (121 papers), Cancer Treatment and Pharmacology (62 papers), Lung Cancer Treatments and Mutations (33 papers), Gastrointestinal Tumor Research and Treatment (26 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (26 papers), Hepatocellular Carcinoma Treatment and Prognosis (26 papers) and HER2/EGFR in Cancer Research (24 papers). The work is most often cited by research in Oncology (5.3k citations), Gastroenterology (971 citations) and Cancer Research (1.9k citations). Yasuhide Yamada has collaborated with scholars based in Japan, United States and United Kingdom. Frequent co-authors include Yasuhiro Shimada, Tetsuya Hamaguchi, Ken Kato, Kuniaki Shirao, Atsushi Ohtsu, Kei Muro, Noboru Yamamoto, Yasuhiro Matsumura, Kazuto Nishio and Takako Eguchi Nakajima. Their work appears in journals such as Journal of Clinical Oncology, Gastroenterology and PLoS ONE.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.